Nivalis Therapeutics Inc. (Nasdaq: NVLS) reported disappointing results from a Phase 2 clinical trial of its cystic fibrosis treatment cavosonstat. Shares of the pharmaceutical plunged $3.68 to close at $2.57.
Disappointing study results for Nivalis Therapeutics
November 29, 2016 at 18:47 PM EST
